Clinical Trial Update: Phase I, Arteriocyte Magellan MAR01 Therapy - Compartment Syndrome and Battlefield Trauma [Phase 1]

View source ↗

Summary

Phase I trial of Arteriocyte Magellan MAR01 Therapy for compartment syndrome (in battlefield trauma) has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Compartment Syndrome

Drugs mentioned

• Magellan MAR01 Therapy

Snippet

Sponsor: Arteriocyte, Inc. | Conditions: Compartment Syndrome | Phase 1 | Status: COMPLETED